Drug design, development and therapy · 2025
Applying the Lasso Model to Identify Risk Factors for Piperacillin-Tazobactam-Induced Leukopenia.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Jiheng, Yuan Xuefeng, Liu Xiaohui, Liu Lihua, Wen Long, Zheng Fang
Аннотация
OBJECTIVE: We conducted a retrospective study to investigate the prevalence, clinical characteristics, and risk factors for leukopenia in patients receiving piperacillin-tazobactam (TZP) therapy.
METHODS: This observational study was conducted from January to December 2022 at a tertiary general hospital in China. All patients over 18 years old who received TZP for more than 48 hours were included. Patients were stratified into adverse drug reactions (ADR) (n=41, TZP-induced leukopenia or neutropenia) and Control (n=8014, no ADR) groups. To balance covariates, 1:2 propensity score matching (PSM) was applied using age, infection type, gender, and comorbidity index, resulting in 82 matched controls for comparative analysis. We employed least absolute shrinkage and selection operator (LASSO) regression to identify risk factors for TZP-induced leukopenia.
RESULTS: A total of 123 patients were analyzed. The average duration of treatment was 10 days (IQR: 7, 19). In 41 patients with TZP-induced leukopenia, the mean onset time was 17.7 ± 6.6 days. Among these, 29 (70.7%) developed neutropenia (including 1 severe case), and 3 (7.3%) had drug-induced fever. Therapy duration (odds ratio (OR) = 1.53, 95% confidence interval (CI) 1.32-1.76) was identified as a significant influencing factor for leukopenia caused by TZP through the LASSO regression screening process.
CONCLUSION: Clinicians should recognize the potential association between TZP administration and leukopenia. Routine hematologic monitoring should emphasize leukocyte trends to assess both therapeutic response and drug safety.
METHODS: This observational study was conducted from January to December 2022 at a tertiary general hospital in China. All patients over 18 years old who received TZP for more than 48 hours were included. Patients were stratified into adverse drug reactions (ADR) (n=41, TZP-induced leukopenia or neutropenia) and Control (n=8014, no ADR) groups. To balance covariates, 1:2 propensity score matching (PSM) was applied using age, infection type, gender, and comorbidity index, resulting in 82 matched controls for comparative analysis. We employed least absolute shrinkage and selection operator (LASSO) regression to identify risk factors for TZP-induced leukopenia.
RESULTS: A total of 123 patients were analyzed. The average duration of treatment was 10 days (IQR: 7, 19). In 41 patients with TZP-induced leukopenia, the mean onset time was 17.7 ± 6.6 days. Among these, 29 (70.7%) developed neutropenia (including 1 severe case), and 3 (7.3%) had drug-induced fever. Therapy duration (odds ratio (OR) = 1.53, 95% confidence interval (CI) 1.32-1.76) was identified as a significant influencing factor for leukopenia caused by TZP through the LASSO regression screening process.
CONCLUSION: Clinicians should recognize the potential association between TZP administration and leukopenia. Routine hematologic monitoring should emphasize leukocyte trends to assess both therapeutic response and drug safety.